

To: 5.1.2e @minvws.nl 5.1.2e @minvws.nl]
 Cc: 5.1.2e @minvws.nl 5.1.2e @minvws.nl]; 5.1.2e @minvws.nl 5.1.2e @minvws.nl]; 5.1.2e ,
 5.1.2e @astrazeneca.com]
 From: 5.1.2e
 Sent: Tue 2/8/2022 10:55:00 AM
 Subject: AZD7442 supply for 2022
 Received: Tue 2/8/2022 10:55:17 AM

Dear Minister Kuipers,

Given the urgent need to protect immune-compromised patients who do not respond to vaccination against Covid, and the limited supply of effective *protective antibody therapy (pre-exposure prophylaxis)*, I wanted to ensure you are fully aware of the current situation:

There is a real unmet need with broad support across society (Clinical Experts 'beroepsgroepen', Patient Groups and Parliament):

- Multiple experts and beroepsgroepen (RECOVAC (Nefrologen), Cobra-KAI (Hematologen)) have formally requested VWS to secure therapy to protect their higher risk vulnerable patients. Experts even requested for early access which many other EU countries have already implemented;
- Patient Advocacy groups representing vulnerable patients have also shared their concerns with VWS about being left behind with no alternative (when vaccination is not effective);
- Parliament last week gave you their full support by unanimously voting to ensure that The Netherlands secures sufficient supply of preventive therapies for vulnerable immune-compromised patients that do not adequately respond to vaccination.

5.1.1c

Urgency for the Netherlands

VWS and RIVM have been kept fully updated of all developments including supply constraints and ordering deadlines which have now passed.

I would like to respectfully bring this to your urgent attention while there is still the possibility to secure sufficient supply for at least high risk vulnerable patients for 2022 according to expert advice. The situation is evolving rapidly with increasing demand from other countries, and there is unfortunately no guarantee we can still supply any further needs for 2022 if you come back to us at a later date.

We urgently request you to finalise any orders for AZD7442 supply for 2022 as soon as possible and remain at your disposal.

Sincerely,

5.1.2e

AstraZeneca

M: 5.1.2e 5.1.2e
 5.1.2e @astrazeneca.com

5.1.2e T: +31 5.1.2e
 5.1.2e @astrazeneca.com

AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.

This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail, highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited and its affiliates may process information, personal data and monitor communications, please see our privacy notice at www.astrazeneca.com